Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: An acute study in parkinsonian levodopa-primed monkeys

Neurology

Volumn 49, Issue 2, 1997, Pages 421-426

  Grondin, Richard ^a,b   Bédard, Paul J ^a,b   Britton, Donald R ^c   Shiosaki, Kazumi ^c  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4,5,5A,6,7,11B HEXAHYDRO 9,10 DIHYDROXY 2 PROPYL 3 THIA 5 AZACYCLOPENT 1 ENA[C]PHENANTHRENE; DOPAMINE 1 RECEPTOR; QUINPIROLE;

ARTICLE; CLINICAL ARTICLE; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DYSKINESIA; GLOBUS PALLIDUS; HEART LEFT VENTRICLE; HUMAN; LOCOMOTION; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 18244424280     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.49.2.421     Document Type: Article

References (45)

1. Kebabian JW, Calne DB. Multiple receptors for dopamine. Nature 1979;277:93-96.
2. Sibley DR, Monsma FJ Jr. Molecular biology of dopamine receptors. Trends Pharmacol Sci 1992;13:61-68.
3. Strange PG. Dopamine receptors in the basal ganglia: relevance to Parkinson's disease. Mov Disord 1993;8:263-270.
4. Nutt JG. Levodopa-induced dyskinesia: review, observations, and speculations. Neurology 1990;40:340-345.
5. Lees AJ, Stern GM. Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1981;44:1020-1023.
6. 3H] spiperone binding. Brain Res 1986;379:294-299.
7. 1 dopamine receptor agonist treatment of Parkinson's disease. J Neural Transm 1987;68:41-50.
8. 1 agonist SKF-38393, reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset. Neurosci Lett 1985;57:37-41.
9. 2 dopamine agonists in MPTP monkeys. Eur J Pharmacol 1988;150:59-66.
10. 1 receptor stimulation in normal and MPTP monkeys. Neurosci Lett 1989;104:223-228.
11. 2 agonists in MPTP-treated primates: functional implications for Parkinson's disease. Neurology 1990;40:927-933.
12. 2 agonist in MPTP-treated monkeys. Exp Neurol 1992;117:185-188.
13. 2 receptor stimulation induces dyskinesia in parkinsonian monkeys. Ann Neurol 1992;31:551-554.
14. 1 agonist, reduces MPTP-induced parkinsonism in monkeys. Eur J Pharmacol 1991;199:389-391.
15. 1 receptor agonist with antiparkinsonian activity in marmosets. Eur J Pharmacol 1992; 229:203-209.
16. 1 receptor agonist, SKF-81297, stimulates motor behaviour of MPTP-lesioned monkeys. Eur J Pharmacol 1993;235:143-147.
17. 2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys. J Pharmacol Exp Ther 1993;267:275-279.
18. 1 receptor desensitization profile in MPTP-lesioned primates. Eur J Pharmacol 1996;309:13-20.
19. Sage JI, Trooskin S, Sonsalla PK, Heikkila R, Duvoisin RC. Long-term duodenal infusion of levodopa for motor fluctuations in parkinsonism. Ann Neurol 1988;24:87-89.
20. Cedarbaum JM, Silvestri M, Kutt H. Sustained enteral administration of levodopa increases and interrupted infusion decreases levodopa dose requirements. Neurology 1990;40: 995-997.
21. Mouradian MM, Heuser IJE, Baronti F, Chase TN. Modifications of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann Neurol 1990;27:18-23.
22. Kurth MC, Tetrud JW, Tanner CM, et al. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with "on-off" fluctuations. Neurology 1993;43:1698-1703.
23. 1 agonist that maintains behavioral efficacy following repeated administration, and characterization of its diacetyl prodrug (ABT-431). J Med Chem 1995;38:3445-3447.
24. 1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease. J Pharmacol Exp Ther 1995;276:150-160.
25. 2 agonist in primates. Clin Neuropharmacol 1992;15:307-309.
26. Mouradian MM, Heuser IJE, Baronti F, Fabbrini G, Juncos JL, Chase TN. Pathogenesis of dyskinesias in Parkinson's disease. Ann Neurol 1989;25:523-526.
27. Schuh LA, Bennett JP Jr. Suppression of dyskinesias in advanced Parkinson's disease. I. Continuous intravenous levodopa shifts dose response for production of dyskinesias but not for relief of parkinsonism in patients with advanced Parkinson's disease. Neurology 1993;43:1545-1550.
28. Marconi R, Lefebvre-Caparros D, Bonnet A-M, Vidailhet M, Dubois B, Agid Y. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology. Mov Disord 1994;9:2-12.
29. Surmeier JD, Reiner A, Levine MS, Ariano MA. Are neostriatal dopamine receptors co-localized? Trends Neurosci 1993;16: 299-305.
30. 2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990;250:1429-1432.
31. 1 receptors to striatonigral neurons. Brain Res 1990; 528:317-322.
32. 1 receptor binding in the striatum following a selective lesion of striatopallidal neurons. Brain Res 1992;590:305-310.
33. 1 dopamine receptor gene. Proc Natl Acad Sci USA 1991;88:4205-4209.
34. 2 dopamine receptors in the basal ganglia of the rat: light and electron microscopy. Neuroscience 1995;65:709-730.
35. Hammond C, Feger J, Bioulac B, Souteyrand JP. Experimental hemiballism in the monkey produced by unilateral kainic acid lesion in corpus Luysii. Brain Res 1979;171:577-580.
36. Hamada I, DeLong MR. Excitotoxic acid lesions of the primate subthalamic nucleus result in transient dyskinesias of the contralateral limbs. J Neurophysiol 1992;68:1850-1858.
37. Crossman AR, Mitchell IJ, Sambrook MA, Jackson A. Chorea and myoclonus in the monkey induced by gamma-aminobutyric acid antagonism into the lentiform complex: the site of drug action and a hypothesis for the neural mechanisms of chorea. Brain 1988;111:1211-1233.
38. Jackson A, Crossman AR. Experimental choreoathetosis produced by injection of gamma-aminobutyric acid into the lentiform nucleus in the monkey. Neurosci Lett 1984;46:41-45.
39. 3H]-2-deoxyglucose in the brain of the monkey during experimental choreiform dyskinesia elicited by injection of gamma-aminobutyric acid antagonist into the subthalamic nucleus. Brain 1985;108:405-422.
40. Crossman AR. A hypothesis on the pathophysiological mecha nisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment. Mov Disord 1990;5:100-108.
41. Parent A, Hazrati L-N. Anatomical aspects of information processing in the primate basal ganglia. Trends Neurosci 1993;16:111-116.
42. Filion M, Tremblay L, Bédard PJ. Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP induced parkinsonism. Brain Res 1991; 547:152-161.
43. Matsumura M, Tremblay L, Richard H, Filion M. Activity of pallidal neurons in the monkey during dyskinesia induced by injection of bicuculline in the external pallidum. Neuroscience 1995;65:59-70.
44. 2 receptor agonists. Eur J Pharmacol 1990;178:115-120.
45. Di Chiara G, Morelli M, Consolo S. Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions. Trends Neurosci 1994;17:228-233.